PARP10

Summary

PARP10 (poly(ADP-ribose) polymerase family member 10, HGNC:25895) is a protein-coding gene on chromosome 8q24.3, encoding Protein mono-ADP-ribosyltransferase PARP10 (Q53GL7). ADP-ribosyltransferase that mediates mono-ADP-ribosylation of glutamate and aspartate residues on target proteins.

Poly(ADP-ribose) polymerases (PARPs), such as PARP10, regulate gene transcription by altering chromatin organization by adding ADP-ribose to histones. PARPs can also function as transcriptional cofactors (Yu et al., 2005 [PubMed 15674325]).

Source: NCBI Gene 84875 — RefSeq curated summary.

At a glance

• GWAS associations: 8
• Clinical variants (ClinVar): 219 total — 1 likely-pathogenic
• Druggable target: yes — 6 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_032789

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25895
Approved symbol	PARP10
Name	poly(ADP-ribose) polymerase family member 10
Location	8q24.3
Locus type	gene with protein product
Status	Approved
Aliases	FLJ14464, ARTD10
Ensembl gene	ENSG00000178685
Ensembl biotype	protein_coding
OMIM	609564
Entrez	84875

Gene structure

Transcript identifiers

Ensembl transcripts: 34 — 26 protein_coding, 4 retained_intron, 3 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000313028, ENST00000313059, ENST00000524918, ENST00000525486, ENST00000525773, ENST00000525879, ENST00000526007, ENST00000526985, ENST00000527262, ENST00000528136, ENST00000528580, ENST00000528625, ENST00000528914, ENST00000528963, ENST00000529311, ENST00000529842, ENST00000530478, ENST00000531537, ENST00000531707, ENST00000532311, ENST00000532660, ENST00000533665, ENST00000534737, ENST00000857398, ENST00000857399, ENST00000857400, ENST00000857401, ENST00000914214, ENST00000966741, ENST00000966742, ENST00000966743, ENST00000966744, ENST00000966745, ENST00000966746

RefSeq mRNA: 2 — MANE Select: NM_032789 NM_001317895, NM_032789

CCDS: CCDS34960, CCDS83331

Canonical transcript exons

ENST00000313028 — 11 exons

Exon	Start	End
ENSE00001250817	143983167	143983811
ENSE00001250825	143984008	143984104
ENSE00001306487	143986055	143986233
ENSE00001309960	143984544	143985328
ENSE00002140641	143977158	143977830
ENSE00003460094	143986358	143986460
ENSE00003467358	143984210	143984431
ENSE00003526489	143982932	143983065
ENSE00003528592	143985412	143985648
ENSE00003529204	143977907	143978081
ENSE00003565027	143985721	143985975

Expression profiles

Bgee: expression breadth ubiquitous, 243 present calls, max score 97.53.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 15.3317 / max 229.1574, expressed in 1630 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
95596	9.8034	1492
95595	4.5695	1310
95598	0.4404	225
95600	0.2472	147
95597	0.1510	52
95601	0.0789	40
95599	0.0412	15

Top tissues by expression

252 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
granulocyte	CL:0000094	97.53	gold quality
pancreatic ductal cell	CL:0002079	97.46	gold quality
right uterine tube	UBERON:0001302	97.18	gold quality
spleen	UBERON:0002106	95.61	gold quality
vermiform appendix	UBERON:0001154	95.45	gold quality
lymph node	UBERON:0000029	95.22	gold quality
right testis	UBERON:0004534	95.01	gold quality
tendon of biceps brachii	UBERON:0008188	94.75	gold quality
left testis	UBERON:0004533	94.73	gold quality
right lobe of liver	UBERON:0001114	94.53	gold quality
right adrenal gland	UBERON:0001233	94.32	gold quality
metanephros cortex	UBERON:0010533	94.31	gold quality
right adrenal gland cortex	UBERON:0035827	94.24	gold quality
monocyte	CL:0000576	93.79	gold quality
leukocyte	CL:0000738	93.58	gold quality
left adrenal gland cortex	UBERON:0035825	93.50	gold quality
left adrenal gland	UBERON:0001234	93.45	gold quality
small intestine Peyer’s patch	UBERON:0003454	93.16	gold quality
blood	UBERON:0000178	93.14	gold quality
adrenal cortex	UBERON:0001235	93.13	gold quality
right ovary	UBERON:0002118	92.83	gold quality
mucosa of transverse colon	UBERON:0004991	92.79	gold quality
parotid gland	UBERON:0001831	92.72	gold quality
upper lobe of left lung	UBERON:0008952	92.66	gold quality
left ovary	UBERON:0002119	92.62	gold quality
testis	UBERON:0000473	92.57	gold quality
bone marrow cell	CL:0002092	92.19	gold quality
right lobe of thyroid gland	UBERON:0001119	92.13	gold quality
cortex of kidney	UBERON:0001225	92.08	gold quality
muscle layer of sigmoid colon	UBERON:0035805	92.02	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-9067	yes	11.37
E-MTAB-9801	yes	6.00
E-ANND-3	no	3.36

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

2 targets.

Target	Regulation
CXCL8	Repression
NFKBIA	Repression

miRNA regulators (miRDB)

7 targeting PARP10, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-661	99.09	65.94	2062
HSA-MIR-6827-5P	98.46	64.88	1256
HSA-MIR-93-3P	98.15	66.65	1309
HSA-MIR-3192-5P	96.98	65.76	1926
HSA-MIR-4485-5P	95.91	59.69	198
HSA-MIR-6846-3P	94.80	65.19	389
HSA-MIR-6090	91.01	62.65	222

Literature-anchored findings (GeneRIF, showing 13)

• novel PARP enzyme involved in the control of cell proliferation (PMID:15674325)
• Overexpression of PARP10 results in loss of cell viability, although down-expression by short hairpin RNA leads to delayed G1 progression and concomitant cell death. (PMID:16455663)
• alternative catalytic mechanism for PARP10 compared to PARP1 in which the acidic target residue of the substrate functionally substitutes for the catalytic glutamate by using substrate-assisted catalysis to transfer ADP-ribose (PMID:18851833)
• study results show that the interaction between PARP10 and NS1 of H5N1 avian influenza virus can change cell cycle, and PARP10 can affect virus replication (PMID:22176891)
• PARP10 binding to PCNA is required for translesion DNA synthesis. (PMID:24695737)
• ARTD10 plays roles in immunity, metabolism ,apoptosis and DNA damage repair. [review] (PMID:24878761)
• PARP10 expression decreased upon fasting, a condition that is characterized by increases in mitochondrial biogenesis. Finally, lower PARP10 expression is associated with increased fatty acid oxidation (PMID:29293500)
• Study shows that PARP10 is downregulated in intrahepatic metastatic hepatocellular carcinoma. Further results provide evidence that deficiency of PARP10 markedly increased the migration and invasion of tumor cells through regulation of epithelial-mesenchymal transition, and that PARP10 expression inhibited tumor metastasis in vivo. (PMID:29515234)
• PARP10 promotes cellular proliferation, and its overexpression alleviates cellular sensitivity to replication stress and fosters the restart of stalled replication forks. In mouse xenograft studies, PARP10 loss reduces the tumorigenesis activity of HeLa cells. Its overexpression results in tumor formation by non-transformed RPE-1 cells. PARP10 may promote cellular transformation by alleviating replication stress. (PMID:30032250)
• PLK1/NF-kappaB feedforward circuit antagonizes the mono-ADP-ribosyltransferase activity of PARP10 and facilitates HCC progression. (PMID:32060423)
• [PARP10 Influences the Proliferation of Colorectal Carcinoma Cells, a Preliminary Study]. (PMID:32392194)
• The mono-ADP-ribosyltransferase ARTD10 regulates the voltage-gated K(+) channel Kv1.1 through protein kinase C delta. (PMID:33059680)
• PARP10 is highly expressed and associated with inferior outcomes in acute myeloid leukemia. (PMID:37506247)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	parp10	ENSDARG00000087145
mus_musculus	Parp10	ENSMUSG00000063268
rattus_norvegicus	Parp10	ENSRNOG00000004361

Paralogs (8): PARP12 (ENSG00000059378), ZC3HAV1 (ENSG00000105939), PARP11 (ENSG00000111224), PARP9 (ENSG00000138496), ZC3HAV1L (ENSG00000146858), TIPARP (ENSG00000163659), PARP14 (ENSG00000173193), PARP15 (ENSG00000173200)

Protein

Protein identifiers

Protein mono-ADP-ribosyltransferase PARP10 — Q53GL7 (reviewed: Q53GL7)

Alternative names: ADP-ribosyltransferase diphtheria toxin-like 10, Poly [ADP-ribose] polymerase 10

All UniProt accessions (15): E9PIA6, E9PIK9, E9PJI2, Q53GL7, E9PK67, E9PLE8, E9PM86, E9PNI7, E9PPE7, E9PPU2, E9PPV8, E9PQQ6, E9PSE7, E9PSG8, F8W8G7

UniProt curated annotations — full annotation on UniProt →

Function. ADP-ribosyltransferase that mediates mono-ADP-ribosylation of glutamate and aspartate residues on target proteins. In contrast to PARP1 and PARP2, it is not able to mediate poly-ADP-ribosylation. Catalyzes mono-ADP-ribosylation of GSK3B, leading to negatively regulate GSK3B kinase activity. Involved in translesion DNA synthesis in response to DNA damage via its interaction with PCNA.

Subunit / interactions. Interacts with MYC. Interacts with PARP14. Interacts (via-PIP box and ubiquitin-interacting motifs) with PCNA.

Subcellular location. Nucleus. Nucleolus. Cytoplasm.

Tissue specificity. Highly expressed in spleen and thymus. Intermediate levels in liver, kidney, pancreas, prostate, testis, ovary, intestine, and leukocytes. Low expression in heart, brain, placenta, lung, skeletal muscle, and colon.

Post-translational modifications. Stimulated through its phosphorylation by CDK2. Acquires CDK-dependent phosphorylation through late-G1 to S phase, and from prometaphase to cytokinesis in the nucleolar organizing regions. Phosphorylation is suppressed in growth-arrested cells. Auto-mono-ADP-ribosylated on glutamate and lysine residues.

Domain organisation. The PIP-box mediates the interaction with PCNA.

Similarity. Belongs to the ARTD/PARP family.

RefSeq proteins (2): NP_001304824, NP_116178* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR012317	Poly(ADP-ribose)pol_cat_dom	Domain
IPR012677	Nucleotide-bd_a/b_plait_sf	Homologous_superfamily
IPR034464	PAR10_RRM1_2	Domain
IPR052056	Mono-ARTD/PARP	Family

Pfam: PF00644, PF23085

Enzyme classification (BRENDA):

• EC 2.4.2.30 — NAD+ ADP-ribosyltransferase (BRENDA: 32 organisms, 193 substrates, 306 inhibitors, 42 Km, 24 kcat entries)

Substrate kinetics (BRENDA)

5 substrates with measured Km, best-characterized 5. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
NAD+	0.002–0.251	25
(ADP-D-RIBOSYL)N-ACTIN	0.011–0.037	7
(ADP-D-RIBOSYL)N-SOYBEAN-TRYPSIN-INHIBITOR	0.03–0.429	6
(ADP-D-RIBOSYL)N-RHOA PROTEIN	0.017	1
N6-ETHENO-NAD+	0.0225	1

Catalyzed reactions (Rhea), 3 shown:

• L-aspartyl-[protein] + NAD(+) = 4-O-(ADP-D-ribosyl)-L-aspartyl-[protein] + nicotinamide (RHEA:54424)
• L-lysyl-[protein] + NAD(+) = N(6)-(ADP-D-ribosyl)-L-lysyl-[protein] + nicotinamide + H(+) (RHEA:58220)
• L-glutamyl-[protein] + NAD(+) = 5-O-(ADP-D-ribosyl)-L-glutamyl-[protein] + nicotinamide (RHEA:58224)

UniProt features (70 total): strand 19, modified residue 11, helix 9, mutagenesis site 8, region of interest 5, sequence conflict 5, sequence variant 3, turn 3, short sequence motif 3, compositionally biased region 2, chain 1, domain 1

Structure

Experimental structures (PDB)

7 structures.

PDB	Method	Resolution (Å)
5LX6	X-RAY DIFFRACTION	1.25
9FRP	X-RAY DIFFRACTION	1.4
9FRS	X-RAY DIFFRACTION	2.02
3HKV	X-RAY DIFFRACTION	2.1
6FXI	X-RAY DIFFRACTION	2.6
9RLS	X-RAY DIFFRACTION	2.75
2DHX	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q53GL7-F1	68.85	0.22

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (11): 101, 106, 140, 378, 423, 431, 663, 882, 916, 916, 1011

Mutagenesis-validated functional residues (8):

Position	Phenotype
650–690	decreased interaction with pcna.
831–838	abolishes interaction with pcna.
882	decreased auto-mono-adp-ribosylation.
888	abolishes catalytic activity; abolishes interaction with parp14.
980–982	strongly decreased catalytic activity.
985	strongly decreased catalytic activity.
987	decreased catalytic activity.
999	does not affect catalytic activity.

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-196807	Nicotinate metabolism
R-HSA-9683610	Maturation of nucleoprotein
R-HSA-9694631	Maturation of nucleoprotein

MSigDB gene sets: 144 (showing top): GOZGIT_ESR1_TARGETS_DN, GOBP_DNA_DAMAGE_TOLERANCE, GOBP_MONOCARBOXYLIC_ACID_METABOLIC_PROCESS, GOBP_NEGATIVE_REGULATION_OF_FIBROBLAST_PROLIFERATION, GOBP_NEGATIVE_REGULATION_OF_NF_KAPPAB_TRANSCRIPTION_FACTOR_ACTIVITY, GOBP_NEGATIVE_REGULATION_OF_MOLECULAR_FUNCTION, GOBP_DNA_DAMAGE_RESPONSE, GOBP_POST_TRANSLATIONAL_PROTEIN_MODIFICATION, GOBP_PROTEIN_POLYUBIQUITINATION, GOBP_DNA_BIOSYNTHETIC_PROCESS, GOBP_NEGATIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS, GOBP_ORGANIC_ACID_METABOLIC_PROCESS, GOBP_PROTEIN_K63_LINKED_UBIQUITINATION, CCAGGGG_MIR331, GOBP_REGULATION_OF_PROTEIN_POLYUBIQUITINATION

GO Biological Process (14): DNA repair (GO:0006281), chromatin organization (GO:0006325), negative regulation of gene expression (GO:0010629), viral protein processing (GO:0019082), translesion synthesis (GO:0019985), obsolete negative regulation of NF-kappaB transcription factor activity (GO:0032088), negative regulation of fibroblast proliferation (GO:0048147), protein poly-ADP-ribosylation (GO:0070212), protein auto-ADP-ribosylation (GO:0070213), negative regulation of protein K63-linked ubiquitination (GO:1900045), nicotinate metabolic process (GO:1901847), DNA damage response (GO:0006974), NAD+ biosynthetic process via the salvage pathway (GO:0034355), negative regulation of DNA-templated transcription (GO:0045892)

GO Molecular Function (13): transcription corepressor activity (GO:0003714), NAD+ poly-ADP-ribosyltransferase activity (GO:0003950), nucleotidyltransferase activity (GO:0016779), K63-linked polyubiquitin modification-dependent protein binding (GO:0070530), DNA-binding transcription factor binding (GO:0140297), NAD+-protein-lysine ADP-ribosyltransferase activity (GO:0140804), NAD+-protein-aspartate ADP-ribosyltransferase activity (GO:0140806), NAD+-protein-glutamate ADP-ribosyltransferase activity (GO:0140807), NAD+-protein mono-ADP-ribosyltransferase activity (GO:1990404), nucleic acid binding (GO:0003676), protein binding (GO:0005515), transferase activity (GO:0016740), glycosyltransferase activity (GO:0016757)

GO Cellular Component (5): nucleus (GO:0005634), nucleolus (GO:0005730), cytoplasm (GO:0005737), Golgi apparatus (GO:0005794), cytosol (GO:0005829)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Metabolism of water-soluble vitamins and cofactors	1
Translation of Structural Proteins	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
NAD+-protein mono-ADP-ribosyltransferase activity	3
post-translational protein modification	2
pentosyltransferase activity	2
binding	2
intracellular membrane-bounded organelle	2
cellular anatomical structure	2
cytoplasm	2
DNA metabolic process	1
DNA damage response	1
cellular component organization	1
gene expression	1
regulation of gene expression	1
negative regulation of macromolecule biosynthetic process	1
viral process	1
viral gene expression	1
DNA damage tolerance	1
DNA synthesis involved in DNA replication	1
negative regulation of cell population proliferation	1
fibroblast proliferation	1
regulation of fibroblast proliferation	1
protein K63-linked ubiquitination	1
regulation of protein K63-linked ubiquitination	1
negative regulation of protein polyubiquitination	1
alkaloid metabolic process	1
monocarboxylic acid metabolic process	1
pyridine-containing compound metabolic process	1
cellular response to stress	1
NAD+ biosynthetic process	1
pyridine nucleotide salvage	1
purine nucleotide salvage	1
DNA-templated transcription	1
regulation of DNA-templated transcription	1
negative regulation of RNA biosynthetic process	1
transcription coregulator activity	1
negative regulation of DNA-templated transcription	1
transferase activity, transferring phosphorus-containing groups	1
polyubiquitin modification-dependent protein binding	1
transcription factor binding	1
catalytic activity, acting on a protein	1
catalytic activity	1

Protein interactions and networks

STRING

1008 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PARP10	MYC	P01106	874
PARP10	PLEC	Q15149	801
PARP10	PARP16	Q8N5Y8	776
PARP10	PARP2	Q9UGN5	766
PARP10	PARP1	P09874	764
PARP10	PARP3	Q9Y6F1	753
PARP10	TRPT1	Q86TN4	732
PARP10	PARP6	Q2NL67	716
PARP10	PARP4	Q9UKK3	711
PARP10	PARP8	Q8N3A8	699
PARP10	SNTB2	Q13425	684
PARP10	MACROD2	A1Z1Q3	662
PARP10	MACROD1	Q9BQ69	661
PARP10	ADPRS	Q9NX46	656
PARP10	TNKS	O95271	625

IntAct

17 interactions, top by confidence:

A	B	Type	Score
MACROD2	PARP10	psi-mi:“MI:1310”(de-ADP-ribosylation reaction)	0.440
	PARP10	psi-mi:“MI:1310”(de-ADP-ribosylation reaction)	0.440
rep	PARP10	psi-mi:“MI:1310”(de-ADP-ribosylation reaction)	0.440
POA1	PARP10	psi-mi:“MI:1310”(de-ADP-ribosylation reaction)	0.440
	PARP10	psi-mi:“MI:0557”(adp ribosylation reaction)	0.440
CASP6	PARP10	psi-mi:“MI:0194”(cleavage reaction)	0.440
CASP8	PARP10	psi-mi:“MI:0194”(cleavage reaction)	0.440
OARD1	PARP10	psi-mi:“MI:0414”(enzymatic reaction)	0.440
PARP10	OARD1	psi-mi:“MI:0414”(enzymatic reaction)	0.440
CA10	ENTPD5	psi-mi:“MI:0914”(association)	0.350
RNF114	DST	psi-mi:“MI:0914”(association)	0.350
RNF166	WASL	psi-mi:“MI:0914”(association)	0.350
PARP10		psi-mi:“MI:0915”(physical association)	0.000

BioGRID (65): UBC (Reconstituted Complex), PARP10 (Affinity Capture-MS), PARP10 (Affinity Capture-MS), PARP10 (Affinity Capture-MS), PARP10 (Affinity Capture-MS), PARP10 (Affinity Capture-MS), PARP10 (Affinity Capture-MS), PARP10 (Affinity Capture-MS), PARP10 (Affinity Capture-MS), Parp14 (Co-localization), PARP10 (Reconstituted Complex), PARP10 (Reconstituted Complex), PARP10 (Affinity Capture-Western), RAN (Biochemical Activity), PARP10 (Affinity Capture-RNA)

ESM2 similar proteins: A1L3T7, A2A3L6, A4IFI1, A7E3N7, A8MYJ7, A8VU90, O94761, O94812, O95153, O95382, P97680, Q0P5G1, Q13671, Q14154, Q3UYR4, Q4V896, Q53GL7, Q569K6, Q58CQ5, Q58EX7, Q66H85, Q6DT37, Q6F5E8, Q6ZVH7, Q76MJ5, Q7TNF8, Q7Z3H0, Q80UU1, Q80UW5, Q8BWA8, Q8BXP5, Q8BYG0, Q8CIE4, Q8CJ00, Q8IYJ3, Q8NAG6, Q8TE82, Q91WA6, Q91WE1, Q921Q7

Diamond homologs: A1Z1Q3, A4W960, A7MG20, A8AI35, B4T2X8, B5F961, B5RBF3, B5XXK9, B7LT90, C9Y0V8, D2TT52, D3RKJ0, D5CE05, E1PL40, E1SDF1, O28751, O59182, O75367, O93327, P0A8D6, P0A8D7, P0A8D8, P0C6F6, P0C6T4, P0C6T6, P0C6T8, P0C6T9, P0C6U0, P0C6U1, P0C6U7, P0C6W3, P0C6W5, P0C6W7, P0C6W8, P0C6W9, P0C6X0, P0C6X6, P67341, P67342, P9WK28

SIGNOR signaling

3 interactions.

A	Effect	B	Mechanism
PARP10	“up-regulates activity”	G3BP1	“post translational modification”
PLK1	“up-regulates activity”	PARP10	phosphorylation
CyclinE/CDK2	“up-regulates activity”	PARP10	phosphorylation

Disease & clinical

Clinical variants and AI predictions

ClinVar

219 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	165
Likely benign	24
Benign	1

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
804412	NM_032789.5(PARP10):c.647_648del (p.Thr216fs)	Likely pathogenic

SpliceAI

2915 predictions. Top by Δscore:

Variant	Effect	Δscore
8:143977826:CGTGG:C	acceptor_gain	1.0000
8:143977831:C:CC	acceptor_gain	1.0000
8:143977901:CCTCA:C	donor_loss	1.0000
8:143977902:CTCAC:C	donor_loss	1.0000
8:143977903:TCAC:T	donor_loss	1.0000
8:143977904:CAC:C	donor_loss	1.0000
8:143977905:A:AC	donor_gain	1.0000
8:143977905:ACCG:A	donor_loss	1.0000
8:143977906:C:CC	donor_gain	1.0000
8:143978077:TCCAC:T	acceptor_gain	1.0000
8:143978078:CCAC:C	acceptor_gain	1.0000
8:143978078:CCACC:C	acceptor_gain	1.0000
8:143978079:CAC:C	acceptor_gain	1.0000
8:143978079:CACC:C	acceptor_gain	1.0000
8:143978080:AC:A	acceptor_gain	1.0000
8:143978080:ACC:A	acceptor_loss	1.0000
8:143978081:CC:C	acceptor_gain	1.0000
8:143978082:C:CA	acceptor_loss	1.0000
8:143978082:C:CC	acceptor_gain	1.0000
8:143978083:T:G	acceptor_loss	1.0000
8:143982927:CTCA:C	donor_loss	1.0000
8:143982929:CA:C	donor_loss	1.0000
8:143982930:A:AC	donor_gain	1.0000
8:143982930:ACACG:A	donor_loss	1.0000
8:143982931:C:CC	donor_gain	1.0000
8:143982931:CA:C	donor_gain	1.0000
8:143983063:CCA:C	acceptor_gain	1.0000
8:143983064:CA:C	acceptor_gain	1.0000
8:143983064:CAC:C	acceptor_gain	1.0000
8:143983066:C:CC	acceptor_gain	1.0000

AlphaMissense

6503 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
8:143977589:G:C	F991L	0.997
8:143977589:G:T	F991L	0.997
8:143977591:A:G	F991L	0.997
8:143977932:G:C	F902L	0.997
8:143977932:G:T	F902L	0.997
8:143977933:A:G	F902S	0.997
8:143977934:A:G	F902L	0.997
8:143977731:A:G	F944S	0.995
8:143977802:G:C	F920L	0.995
8:143977802:G:T	F920L	0.995
8:143977803:A:G	F920S	0.995
8:143977804:A:G	F920L	0.995
8:143977598:G:C	F988L	0.994
8:143977598:G:T	F988L	0.994
8:143977600:A:G	F988L	0.994
8:143977982:A:C	Y886D	0.994
8:143977631:G:C	S977R	0.993
8:143977631:G:T	S977R	0.993
8:143977633:T:G	S977R	0.993
8:143977730:G:C	F944L	0.993
8:143977730:G:T	F944L	0.993
8:143977732:A:G	F944L	0.993
8:143977557:A:T	I1002N	0.992
8:143977560:A:G	L1001P	0.992
8:143977584:T:A	D993V	0.992
8:143977590:A:G	F991S	0.992
8:143977596:A:T	V989D	0.992
8:143977739:C:A	K941N	0.992
8:143977739:C:G	K941N	0.992
8:143977557:A:G	I1002T	0.991

dbSNP variants (sampled 300 via entrez): RS1000129401 (8:144001650 G>A), RS1000247414 (8:144001509 C>A), RS1000410038 (8:144008243 G>C), RS1000602570 (8:143990929 A>G), RS1000670787 (8:143995847 G>A), RS1000881324 (8:143979100 A>G), RS1000954880 (8:143984394 T>C), RS1000974009 (8:143978829 A>C,G), RS1001264450 (8:143993141 G>A,T), RS1001610286 (8:143986771 C>G,T), RS1001763387 (8:143987022 T>G), RS1001796389 (8:144003389 A>G), RS1001911072 (8:144003018 C>A), RS1002023312 (8:144009384 G>C,T), RS1002271584 (8:143992192 A>C)

Disease associations

OMIM: gene MIM:609564 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

8 associations (top):

Study	Trait	p-value
GCST002541_68	Menarche (age at onset)	1.000000e-08
GCST008103_86	Bipolar disorder	1.000000e-06
GCST008115_8	Bipolar I disorder	2.000000e-08
GCST010703_132	Brain morphology (MOSTest)	3.000000e-08
GCST90002390_617	Mean corpuscular hemoglobin	4.000000e-13
GCST90002392_525	Mean corpuscular volume	2.000000e-15
GCST90002404_105	Red cell distribution width	1.000000e-22
GCST90020026_753	Hip index	3.000000e-09

EFO canonical traits (6, from GWAS)

EFO ID	Trait name
EFO:0004703	age at menarche
EFO:0009963	bipolar I disorder
EFO:0004346	neuroimaging measurement
EFO:0004527	mean corpuscular hemoglobin
EFO:0009188	Red cell distribution width
EFO:0008039	BMI-adjusted hip circumference

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL2429708 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

6 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 39,549 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1094636	NIRAPARIB	4	6,433
CHEMBL1173055	RUCAPARIB	4	7,009
CHEMBL3137320	TALAZOPARIB	4	5,534
CHEMBL521686	OLAPARIB	4	13,038
CHEMBL4112930	PAMIPARIB	3	2,114
CHEMBL506871	VELIPARIB	3	5,421

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — Mono-ADP-ribosylating PARPs

Most potent curated ligand interactions (3 total), top 3:

Ligand	Action	Affinity	Parameter
compound 8a [PMID: 35500474]	Inhibition	6.85	pIC50
compound 32 [PMID: 30006177]	Inhibition	6.64	pIC50
OUL35	Inhibition	6.48	pIC50

ChEMBL bioactivities

286 potent at pChembl≥5 of 331 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.11	IC50	7.8	nM	CHEMBL5404785
8.11	IC50	7.762	nM	CHEMBL5404785
7.97	IC50	10.8	nM	CHEMBL5402698
7.60	IC50	25	nM	CHEMBL5431108
7.60	IC50	25.12	nM	CHEMBL5431108
6.93	IC50	117.5	nM	CHEMBL5404785
6.92	IC50	120	nM	CHEMBL5404785
6.89	IC50	130	nM	CHEMBL5192839
6.87	IC50	134.9	nM	CHEMBL5181947
6.87	IC50	134.9	nM	CHEMBL5192839
6.85	IC50	140	nM	CHEMBL5181947
6.85	IC50	140	nM	CHEMBL5176874
6.82	IC50	150	nM	CHEMBL5200358
6.82	IC50	151.4	nM	CHEMBL5200358
6.81	IC50	154.9	nM	CHEMBL5187187
6.81	IC50	156	nM	CHEMBL5207717
6.80	IC50	160	nM	CHEMBL5187187
6.80	IC50	160	nM	CHEMBL5200521
6.80	IC50	158.5	nM	CHEMBL5200521
6.75	IC50	180	nM	CHEMBL4287262
6.75	IC50	180	nM	CHEMBL5431108
6.73	IC50	186.2	nM	CHEMBL4287262
6.73	IC50	186.2	nM	CHEMBL5431108
6.65	IC50	223.9	nM	CHEMBL6170252
6.64	IC50	230	nM	CHEMBL4208737
6.63	IC50	234.4	nM	CHEMBL4208737
6.61	IC50	245.5	nM	CHEMBL4128574
6.60	IC50	250	nM	CHEMBL4128574
6.54	IC50	290	nM	CHEMBL5186967
6.54	IC50	288.4	nM	CHEMBL5186967
6.51	IC50	310	nM	CHEMBL5181107
6.51	IC50	309	nM	CHEMBL5181107
6.50	IC50	320	nM	CHEMBL5421878
6.50	IC50	316.2	nM	CHEMBL5421878
6.49	IC50	325	nM	CHEMBL5395820
6.48	IC50	329	nM	CHEMBL1438938
6.48	IC50	330	nM	CHEMBL1438938
6.46	IC50	350	nM	OLAPARIB
6.42	IC50	382	nM	OLAPARIB
6.42	IC50	377	nM	CHEMBL5571636
6.41	IC50	390	nM	CHEMBL4125748
6.41	IC50	387.3	nM	CHEMBL4125748
6.40	IC50	398.1	nM	CHEMBL4129789
6.40	IC50	400	nM	CHEMBL4129789
6.34	IC50	460	nM	CHEMBL4130035
6.34	IC50	460	nM	CHEMBL4127497
6.34	IC50	457.1	nM	CHEMBL4127497
6.33	IC50	467.7	nM	CHEMBL4129923
6.33	IC50	467.7	nM	CHEMBL4130035
6.33	IC50	470	nM	CHEMBL4129923

PubChem BioAssay actives

287 with measured affinity, of 484 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
5,8-dimethoxy-[1,2,4]triazolo[3,4-b][1,3]benzothiazol-1-amine	1965928: Inhibition of N-terminal MBP tagged/C-terminal PARP10 (unknown origin) expressed in Escherichia coli in presence of NAD+ by proximity enhanced assay	ic50	0.0078	uM
4-[[3-[3-(5-bromofuran-2-yl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazine-7-carbonyl]-4-fluorophenyl]methyl]-2H-phthalazin-1-one	2012702: Inhibition of PARP10 (unknown origin) using biotinylated NAD+ as substrate by luminescence assay	ic50	0.0108	uM
6-methyl-[1,2,4]triazolo[3,4-b][1,3]benzothiazol-1-amine	1965928: Inhibition of N-terminal MBP tagged/C-terminal PARP10 (unknown origin) expressed in Escherichia coli in presence of NAD+ by proximity enhanced assay	ic50	0.0250	uM
6-(cyclopentylmethoxy)-2,3-dihydrophthalazine-1,4-dione	1868249: Inhibition of human PARP-10 using NAD+ as substrate incubated for 10 mins by fluorescence based analysis	ic50	0.1300	uM
6-(cyclohexylmethoxy)-2,3-dihydrophthalazine-1,4-dione	1868249: Inhibition of human PARP-10 using NAD+ as substrate incubated for 10 mins by fluorescence based analysis	ic50	0.1349	uM
4-[2-fluoro-5-[(4-oxo-3H-phthalazin-1-yl)methyl]benzoyl]-N-[4-[(4-methoxyphenyl)carbamoyl]phenyl]piperazine-1-carboxamide	1868363: Inhibition of PARP-10 (unknown origin)	ic50	0.1400	uM
6-[(2-fluorophenyl)methoxy]-2,3-dihydrophthalazine-1,4-dione	1868249: Inhibition of human PARP-10 using NAD+ as substrate incubated for 10 mins by fluorescence based analysis	ic50	0.1500	uM
6-(cyclobutylmethoxy)-2,3-dihydrophthalazine-1,4-dione	1868249: Inhibition of human PARP-10 using NAD+ as substrate incubated for 10 mins by fluorescence based analysis	ic50	0.1549	uM
4-[(8-methyl-4-oxo-7-prop-1-ynyl-3H-quinazolin-2-yl)methylsulfanyl]benzoic acid	1869173: Inhibition of PARP10 (unknown origin)	ic50	0.1560	uM
6-(thiophen-3-ylmethoxy)-2,3-dihydrophthalazine-1,4-dione	1868249: Inhibition of human PARP-10 using NAD+ as substrate incubated for 10 mins by fluorescence based analysis	ic50	0.1585	uM
4-(4-carbamoylphenoxy)benzoic acid	1405638: Inhibition of C-terminal His-tagged human ARTD10 (809 to 1017 residues) expressed in Escherichia coli Rosetta2 (DE3) using SRPK2 as substrate after 13 hrs in presence of NAD+	ic50	0.1800	uM
4-[(2-fluorophenyl)methoxy]benzamide	1405638: Inhibition of C-terminal His-tagged human ARTD10 (809 to 1017 residues) expressed in Escherichia coli Rosetta2 (DE3) using SRPK2 as substrate after 13 hrs in presence of NAD+	ic50	0.2300	uM
4-[3-[4-(3-fluorophenyl)piperidine-1-carbonyl]phenoxy]benzamide	1496062: Inhibition of full length recombinant His6-tagged human PARP10 expressed in Escherichia coli BL21(DE3) preincubated for 15 mins followed by biotinylated NAD+ addition by chemiluminescence assay	ic50	0.2455	uM
4-(cyclobutylmethoxy)benzamide	1868249: Inhibition of human PARP-10 using NAD+ as substrate incubated for 10 mins by fluorescence based analysis	ic50	0.2884	uM
6-(cyclopropylmethoxy)-2,3-dihydrophthalazine-1,4-dione	1868249: Inhibition of human PARP-10 using NAD+ as substrate incubated for 10 mins by fluorescence based analysis	ic50	0.3090	uM
[1,2,4]triazolo[3,4-b][1,3]benzothiazole-5,8-diol	1965915: Inhibition of N-terminal MBP tagged/C-terminal PARP10 (unknown origin) expressed in Escherichia coli in presence of NAD+	ic50	0.3162	uM
5-(trifluoromethyl)-4-[[(2S)-1-[3-[4-[5-(trifluoromethyl)pyrimidin-2-yl]piperazine-1-carbonyl]azetidin-1-yl]propan-2-yl]amino]-1H-pyridazin-6-one	1965304: Inhibition of human recombinant N-terminal FLAG-tagged / C-terminal Strep-tagged PARP10 (805 to 1025 end residues) expressed in baculovirus infected Sf9 cells expression system incubated for 1 hr by ELISA assay	ic50	0.3250	uM
4-(4-carbamoylphenoxy)benzamide	1496070: Inhibition of full length recombinant His6-tagged PARP10 catalytic domain (unknown origin) expressed in Escherichia coli BL21(DE3) by fluorescence based assay	ic50	0.3290	uM
Olaparib	2019996: Inhibition of human N-terminal FLAG-tagged/C-terminal Strep-tagged recombinant PARP10 (805 to 1025 residues) expressed in Sf9 cells	ic50	0.3500	uM
2-[(2S)-1-oxo-1-[4-[5-(trifluoromethyl)pyrimidin-2-yl]piperazin-1-yl]propan-2-yl]indazole-7-carboxamide	2096830: Inhibition of PARP10 (unknown origin) measured after 1 hr incubation by microplate reader assay	ic50	0.3770	uM
4-[3-[4-(4-fluorophenyl)-4-hydroxypiperidine-1-carbonyl]phenoxy]benzamide	1496062: Inhibition of full length recombinant His6-tagged human PARP10 expressed in Escherichia coli BL21(DE3) preincubated for 15 mins followed by biotinylated NAD+ addition by chemiluminescence assay	ic50	0.3873	uM
4-[3-[4-(4-fluorophenyl)piperidine-1-carbonyl]phenoxy]benzamide	1496062: Inhibition of full length recombinant His6-tagged human PARP10 expressed in Escherichia coli BL21(DE3) preincubated for 15 mins followed by biotinylated NAD+ addition by chemiluminescence assay	ic50	0.3981	uM
4-[3-[4-(2-fluorophenyl)piperazine-1-carbonyl]phenoxy]benzamide	1496062: Inhibition of full length recombinant His6-tagged human PARP10 expressed in Escherichia coli BL21(DE3) preincubated for 15 mins followed by biotinylated NAD+ addition by chemiluminescence assay	ic50	0.4571	uM
4-[3-[4-(3-fluorophenyl)piperazine-1-carbonyl]phenoxy]benzamide	1496062: Inhibition of full length recombinant His6-tagged human PARP10 expressed in Escherichia coli BL21(DE3) preincubated for 15 mins followed by biotinylated NAD+ addition by chemiluminescence assay	ic50	0.4600	uM
4-[3-[4-(2-fluorophenyl)piperidine-1-carbonyl]phenoxy]benzamide	1496062: Inhibition of full length recombinant His6-tagged human PARP10 expressed in Escherichia coli BL21(DE3) preincubated for 15 mins followed by biotinylated NAD+ addition by chemiluminescence assay	ic50	0.4677	uM
3-(4-carbamoylphenoxy)benzamide	1869165: Inhibition of C-terminal his-tagged human PARP10 expressed in Escherichia coli Rosette2 (DE3)	ic50	0.4800	uM
5,8-dimethoxy-[1,2,4]triazolo[3,4-b][1,3]benzothiazole	1965915: Inhibition of N-terminal MBP tagged/C-terminal PARP10 (unknown origin) expressed in Escherichia coli in presence of NAD+	ic50	0.4898	uM
Rucaparib	1428394: Inhibition of full length recombinant human His6-tagged PARP10 expressed in Escherichia coli BL21(DE3) preincubated for 15 mins followed by biotinylated NAD+ addition by chemiluminescence assay	ic50	0.5623	uM
4-[3-(4-phenylpiperidine-1-carbonyl)phenoxy]benzamide	1496062: Inhibition of full length recombinant His6-tagged human PARP10 expressed in Escherichia coli BL21(DE3) preincubated for 15 mins followed by biotinylated NAD+ addition by chemiluminescence assay	ic50	0.5754	uM
4-(cyclopentylmethoxy)benzamide	1868249: Inhibition of human PARP-10 using NAD+ as substrate incubated for 10 mins by fluorescence based analysis	ic50	0.5888	uM
4-[3-(3-phenylpiperidine-1-carbonyl)phenoxy]benzamide	1496062: Inhibition of full length recombinant His6-tagged human PARP10 expressed in Escherichia coli BL21(DE3) preincubated for 15 mins followed by biotinylated NAD+ addition by chemiluminescence assay	ic50	0.6000	uM
4-(cyclopropylmethoxy)benzamide	1868249: Inhibition of human PARP-10 using NAD+ as substrate incubated for 10 mins by fluorescence based analysis	ic50	0.6000	uM
4-(cyclobutylmethoxy)-2-fluorobenzamide	1868249: Inhibition of human PARP-10 using NAD+ as substrate incubated for 10 mins by fluorescence based analysis	ic50	0.6166	uM
4-(4-formylphenoxy)benzamide	1405638: Inhibition of C-terminal His-tagged human ARTD10 (809 to 1017 residues) expressed in Escherichia coli Rosetta2 (DE3) using SRPK2 as substrate after 13 hrs in presence of NAD+	ic50	0.6166	uM
5-methyl-6-(1H-pyrrolo[2,3-b]pyridin-5-yl)-3,4-dihydro-2H-isoquinolin-1-one	1515545: Inhibition of human PARP10 catalytic domain assessed as reduction in MARylation of His6-tagged SRPK2 substrate after 60 mins in presence of NAD+ by chemifluorescence assay	ic50	0.7079	uM
4-cyclobutyloxybenzamide	1405638: Inhibition of C-terminal His-tagged human ARTD10 (809 to 1017 residues) expressed in Escherichia coli Rosetta2 (DE3) using SRPK2 as substrate after 13 hrs in presence of NAD+	ic50	0.7200	uM
methyl (Z)-4-(3-carbamoylanilino)-4-oxobut-2-enoate	1202205: Inhibition of hexahistidine-tagged full length human recombinant ARTD10 expressed in Escherichia coli BL21(DE3) assessed as Inhibition of ADP-ribosyltransferase activity incubated for 15 mins using biotin-NAD+ by chemiluminescence detection based assay	ic50	0.7586	uM
4-[3-(3-phenylpyrrolidine-1-carbonyl)phenoxy]benzamide	1496062: Inhibition of full length recombinant His6-tagged human PARP10 expressed in Escherichia coli BL21(DE3) preincubated for 15 mins followed by biotinylated NAD+ addition by chemiluminescence assay	ic50	0.7762	uM
8-methoxy-4H-thieno[2,3-c]isoquinolin-5-one	1833808: Inhibition of PARP10 (809 to 1017 residues) (unknown origin) expressed in Escherichia coli using NAD+ as substrate incubated for 13 hrs by fluorescence based assay	ic50	0.7800	uM
8-ethoxy-4H-thieno[2,3-c]isoquinolin-5-one	1833808: Inhibition of PARP10 (809 to 1017 residues) (unknown origin) expressed in Escherichia coli using NAD+ as substrate incubated for 13 hrs by fluorescence based assay	ic50	0.9200	uM
4-(cyclohexylmethoxy)-2-fluorobenzamide	1868249: Inhibition of human PARP-10 using NAD+ as substrate incubated for 10 mins by fluorescence based analysis	ic50	0.9550	uM
ethyl 1-[3-(4-carbamoylphenoxy)benzoyl]piperidine-4-carboxylate	1496062: Inhibition of full length recombinant His6-tagged human PARP10 expressed in Escherichia coli BL21(DE3) preincubated for 15 mins followed by biotinylated NAD+ addition by chemiluminescence assay	ic50	1.0600	uM
4-[3-(4-phenylpiperazine-1-carbonyl)phenoxy]benzamide	1496062: Inhibition of full length recombinant His6-tagged human PARP10 expressed in Escherichia coli BL21(DE3) preincubated for 15 mins followed by biotinylated NAD+ addition by chemiluminescence assay	ic50	1.0715	uM
6-(1H-indol-5-yl)-5-methyl-3,4-dihydro-2H-isoquinolin-1-one	1515545: Inhibition of human PARP10 catalytic domain assessed as reduction in MARylation of His6-tagged SRPK2 substrate after 60 mins in presence of NAD+ by chemifluorescence assay	ic50	1.0965	uM
4-[3-(2-phenylpiperidine-1-carbonyl)phenoxy]benzamide	1496062: Inhibition of full length recombinant His6-tagged human PARP10 expressed in Escherichia coli BL21(DE3) preincubated for 15 mins followed by biotinylated NAD+ addition by chemiluminescence assay	ic50	1.0965	uM
5,7-dimethoxy-[1,2,4]triazolo[3,4-b][1,3]benzothiazole	1965915: Inhibition of N-terminal MBP tagged/C-terminal PARP10 (unknown origin) expressed in Escherichia coli in presence of NAD+	ic50	1.1000	uM
4-phenoxybenzamide	1405638: Inhibition of C-terminal His-tagged human ARTD10 (809 to 1017 residues) expressed in Escherichia coli Rosetta2 (DE3) using SRPK2 as substrate after 13 hrs in presence of NAD+	ic50	1.1000	uM
6-(3-chlorophenyl)-3,4-dihydro-2H-isoquinolin-1-one	1515545: Inhibition of human PARP10 catalytic domain assessed as reduction in MARylation of His6-tagged SRPK2 substrate after 60 mins in presence of NAD+ by chemifluorescence assay	ic50	1.1000	uM
4-(5-chloro-2-methoxyphenyl)-N-[5-[[1-[2-fluoro-5-[(4-oxo-3H-phthalazin-1-yl)methyl]benzoyl]piperidin-4-yl]methoxy]-1,3,4-thiadiazol-2-yl]-6-methylpyridine-3-carboxamide	2080542: Inhibition of PARP10 (unknown origin)	ic50	1.1030	uM
6-[(3-bromophenyl)methoxy]-2,3-dihydrophthalazine-1,4-dione	1868249: Inhibition of human PARP-10 using NAD+ as substrate incubated for 10 mins by fluorescence based analysis	ic50	1.1482	uM

CTD chemical–gene interactions

39 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Air Pollutants	affects expression, increases abundance, decreases expression	2
Nickel	increases expression	2
Tobacco Smoke Pollution	decreases expression	2
Valproic Acid	increases methylation, decreases expression	2
Particulate Matter	decreases expression, increases abundance	2
aristolochic acid I	increases expression	1
FR900359	increases phosphorylation	1
SBI-797812	increases activity	1
bisphenol A	decreases methylation	1
diisononyl phthalate	increases methylation	1
beta-lapachone	increases expression, decreases expression	1
sodium arsenite	increases expression	1
pentanal	increases expression	1
di-n-butylphosphoric acid	affects expression	1
veliparib	affects binding	1
jinfukang	increases expression, affects cotreatment	1
(+)-JQ1 compound	decreases expression	1
Temozolomide	increases expression	1
Sunitinib	increases expression	1
Acetaminophen	decreases expression	1
Arsenic	affects expression	1
Vehicle Emissions	decreases expression, increases abundance	1
Benzo(a)pyrene	decreases methylation	1
Cisplatin	affects cotreatment, increases expression	1
Doxorubicin	decreases expression	1
Estradiol	decreases expression	1
Ethyl Methanesulfonate	increases expression	1
Formaldehyde	increases expression	1
Methyl Methanesulfonate	increases expression	1
NAD	decreases abundance	1

ChEMBL screening assays

70 unique, capped per target: 69 binding, 1 admet

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL2433125	Binding	Inhibition of human ARTD10 (809 to 1017) using NAD+ as substrate at 1 uM by fluorescence assay	Discovery of tankyrase inhibiting flavones with increased potency and isoenzyme selectivity. — J Med Chem
CHEMBL4345424	ADMET	Inhibition of human recombinant N-terminal TEV-cleavgae site-fused-FLAG/Polyhis-tagged PARP10 (2 to 583 residues) expressed in Escherichia coli assessed as reduction in auto-PARylation using histone as substrate measured after 45 mins in pr	Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer. — J Med Chem

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1GU	Abcam A-549 PARP10 KO 1	Cancer cell line	Male
CVCL_B2PD	Abcam A-549 PARP10 KO 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.